Celiac Disease Drugs Market: Allied Market Research

Upcoming

2023

Celiac Disease Drugs Market

by Drugs (First Line of Treatment, Second Line of Treatment): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals	Report Code: A03610	Nov 2023 \| Pages: NA
Tables: NA	Charts: NA	Formats*: Single User License, Five User License & Enterprise User License Data Pack Excel License It comes with the additional cost of $2500.00 contact sales.

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Celiac Disease Drugs Market

Request Now !

Celiac disease is a genetic, auto-immune disorder that affects the small intestine upon consumption of gluten. Celiac diseases may contribute to various diseases and disorders such as low bone density, neurological disorders, infertility, and certain cancers. There are no drugs available that can treat celiac diseases.

Growth in the prevalence of celiac diseases is the major factor that drives the growth of the celiac disease drugs market. In addition, the dependence on gluten rich food and trends of ready-to-use packaged food have increased the demand for the celiac disease drugs market.

Furthermore, rise in healthcare expenditure and increase in investments in celiac disease awareness programs by governments and private organizations such as National Program for the Detection and Control of Celiac Disease are anticipated to boost the market growth. However, stringent government regulations for drug approval hinder the growth. Ongoing R&D activities related to celiac disease drugs are anticipated to present new opportunities for the market.

The market is segmented on the basis of drugs and geography. Based on drugs, the market is categorized into first line of treatment and second line of treatment. The geographical breakdown of each of the aforesaid segments has been covered for North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits

The study provides an in-depth analysis of the global celiac disease drugs market with current trends and future estimations to elucidate investment pockets.
Comprehensive analysis of factors that drive and restrict the growth of the market has been provided.
The report provides a quantitative analysis to help stakeholders to capitalize on prevailing market opportunities.
Extensive analysis of different segments helps understand various products of the market.
Key players have been profiled and their strategies thoroughly analyzed, which predict the competitive outlook of the market.

Celiac Disease Drugs Market Report Highlights

Aspects	Details
By Drugs	First Line of Treatment Second Line of Treatment
By Region	North America (U.S., Canada, Mexico) Europe (France, Germany, Italy, Spain, UK, Rest of Europe) Asia-Pacific (China, Japan, India, Rest of Asia-Pacific) LAMEA (Latin America, The Middle East, Africa)
Key Market Players	BiolineRx Ltd., Innovate Biopharmaceuticals, Merck & Co., Inc., Novartis AG, Pfizer Inc., Immunomedics, Inc., F. Hoffmann-La Roche, Bristol-Myers Squibb Company, ImmusanT, Inc., Johnson & Johnson

CHAPTER 1: INTRODUCTION
- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits
- 1.4. Research Methodology
  - 1.4.1. Primary Research
  - 1.4.2. Secondary Research
  - 1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
- 3.1. Market Definition and Scope
- 3.2. Key Findings
  - 3.2.1. Top Investment Pockets
  - 3.2.2. Top Winning Strategies
- 3.3. Porter's Five Forces Analysis
  - 3.3.1. Bargaining Power of Suppliers
  - 3.3.2. Threat of New Entrants
  - 3.3.3. Threat of Substitutes
  - 3.3.4. Competitive Rivalry
  - 3.3.5. Bargaining Power among Buyers
- 3.5. Market Dynamics
  - 3.5.1. Drivers
  - 3.5.2. Restraints
  - 3.5.3. Opportunities
- 3.6. COVID-19 Impact Analysis
CHAPTER 4: CELIAC DISEASE DRUGS MARKET, BY DRUGS
- 4.1. Market Overview
  - 4.1.1 Market Size and Forecast, By Drugs
- 4.2. First Line Of Treatment
  - 4.2.1. Key Market Trends, Growth Factors and Opportunities
  - 4.2.2. Market Size and Forecast, By Region
  - 4.2.3. Market Share Analysis, By Country
- 4.3. Second Line Of Treatment
  - 4.3.1. Key Market Trends, Growth Factors and Opportunities
  - 4.3.2. Market Size and Forecast, By Region
  - 4.3.3. Market Share Analysis, By Country
CHAPTER 5: CELIAC DISEASE DRUGS MARKET, BY REGION
- 5.1. Market Overview
  - 5.1.1 Market Size and Forecast, By Region
- 5.2. North America
  - 5.2.1. Key Market Trends and Opportunities
  - 5.2.2. Market Size and Forecast, By Drugs
  - 5.2.3. Market Size and Forecast, By Country
  - 5.2.4. U.S. Celiac Disease Drugs Market
    - 5.2.4.1. Market Size and Forecast, By Drugs
  - 5.2.5. Canada Celiac Disease Drugs Market
    - 5.2.5.1. Market Size and Forecast, By Drugs
  - 5.2.6. Mexico Celiac Disease Drugs Market
    - 5.2.6.1. Market Size and Forecast, By Drugs
- 5.3. Europe
  - 5.3.1. Key Market Trends and Opportunities
  - 5.3.2. Market Size and Forecast, By Drugs
  - 5.3.3. Market Size and Forecast, By Country
  - 5.3.4. France Celiac Disease Drugs Market
    - 5.3.4.1. Market Size and Forecast, By Drugs
  - 5.3.5. Germany Celiac Disease Drugs Market
    - 5.3.5.1. Market Size and Forecast, By Drugs
  - 5.3.6. Italy Celiac Disease Drugs Market
    - 5.3.6.1. Market Size and Forecast, By Drugs
  - 5.3.7. Spain Celiac Disease Drugs Market
    - 5.3.7.1. Market Size and Forecast, By Drugs
  - 5.3.8. UK Celiac Disease Drugs Market
    - 5.3.8.1. Market Size and Forecast, By Drugs
  - 5.3.9. Russia Celiac Disease Drugs Market
    - 5.3.9.1. Market Size and Forecast, By Drugs
  - 5.3.10. Rest Of Europe Celiac Disease Drugs Market
    - 5.3.10.1. Market Size and Forecast, By Drugs
- 5.4. Asia-Pacific
  - 5.4.1. Key Market Trends and Opportunities
  - 5.4.2. Market Size and Forecast, By Drugs
  - 5.4.3. Market Size and Forecast, By Country
  - 5.4.4. China Celiac Disease Drugs Market
    - 5.4.4.1. Market Size and Forecast, By Drugs
  - 5.4.5. Japan Celiac Disease Drugs Market
    - 5.4.5.1. Market Size and Forecast, By Drugs
  - 5.4.6. India Celiac Disease Drugs Market
    - 5.4.6.1. Market Size and Forecast, By Drugs
  - 5.4.7. South Korea Celiac Disease Drugs Market
    - 5.4.7.1. Market Size and Forecast, By Drugs
  - 5.4.8. Australia Celiac Disease Drugs Market
    - 5.4.8.1. Market Size and Forecast, By Drugs
  - 5.4.9. Thailand Celiac Disease Drugs Market
    - 5.4.9.1. Market Size and Forecast, By Drugs
  - 5.4.10. Malaysia Celiac Disease Drugs Market
    - 5.4.10.1. Market Size and Forecast, By Drugs
  - 5.4.11. Indonesia Celiac Disease Drugs Market
    - 5.4.11.1. Market Size and Forecast, By Drugs
  - 5.4.12. Rest of Asia Pacific Celiac Disease Drugs Market
    - 5.4.12.1. Market Size and Forecast, By Drugs
- 5.5. LAMEA
  - 5.5.1. Key Market Trends and Opportunities
  - 5.5.2. Market Size and Forecast, By Drugs
  - 5.5.3. Market Size and Forecast, By Country
  - 5.5.4. Brazil Celiac Disease Drugs Market
    - 5.5.4.1. Market Size and Forecast, By Drugs
  - 5.5.5. South Africa Celiac Disease Drugs Market
    - 5.5.5.1. Market Size and Forecast, By Drugs
  - 5.5.6. Saudi Arabia Celiac Disease Drugs Market
    - 5.5.6.1. Market Size and Forecast, By Drugs
  - 5.5.7. UAE Celiac Disease Drugs Market
    - 5.5.7.1. Market Size and Forecast, By Drugs
  - 5.5.8. Argentina Celiac Disease Drugs Market
    - 5.5.8.1. Market Size and Forecast, By Drugs
  - 5.5.9. Rest of LAMEA Celiac Disease Drugs Market
    - 5.5.9.1. Market Size and Forecast, By Drugs
CHAPTER 6: COMPETITIVE LANDSCAPE
- 6.1. Introduction
- 6.2. Top Winning Strategies
- 6.3. Product Mapping Of Top 10 Player
- 6.4. Competitive Dashboard
- 6.5. Competitive Heatmap
- 6.6. Top Player Positioning,2022
CHAPTER 7: COMPANY PROFILES
- 7.1. F. Hoffmann-La Roche
  - 7.1.1. Company Overview
  - 7.1.2. Key Executives
  - 7.1.3. Company Snapshot
  - 7.1.4. Operating Business Segments
  - 7.1.5. Product Portfolio
  - 7.1.6. Business Performance
  - 7.1.7. Key Strategic Moves and Developments
- 7.2. Merck And Co., Inc.
  - 7.2.1. Company Overview
  - 7.2.2. Key Executives
  - 7.2.3. Company Snapshot
  - 7.2.4. Operating Business Segments
  - 7.2.5. Product Portfolio
  - 7.2.6. Business Performance
  - 7.2.7. Key Strategic Moves and Developments
- 7.3. Johnson And Johnson
  - 7.3.1. Company Overview
  - 7.3.2. Key Executives
  - 7.3.3. Company Snapshot
  - 7.3.4. Operating Business Segments
  - 7.3.5. Product Portfolio
  - 7.3.6. Business Performance
  - 7.3.7. Key Strategic Moves and Developments
- 7.4. BiolineRx Ltd.
  - 7.4.1. Company Overview
  - 7.4.2. Key Executives
  - 7.4.3. Company Snapshot
  - 7.4.4. Operating Business Segments
  - 7.4.5. Product Portfolio
  - 7.4.6. Business Performance
  - 7.4.7. Key Strategic Moves and Developments
- 7.5. Pfizer Inc.
  - 7.5.1. Company Overview
  - 7.5.2. Key Executives
  - 7.5.3. Company Snapshot
  - 7.5.4. Operating Business Segments
  - 7.5.5. Product Portfolio
  - 7.5.6. Business Performance
  - 7.5.7. Key Strategic Moves and Developments
- 7.6. Innovate Biopharmaceuticals
  - 7.6.1. Company Overview
  - 7.6.2. Key Executives
  - 7.6.3. Company Snapshot
  - 7.6.4. Operating Business Segments
  - 7.6.5. Product Portfolio
  - 7.6.6. Business Performance
  - 7.6.7. Key Strategic Moves and Developments
- 7.7. ImmusanT, Inc.
  - 7.7.1. Company Overview
  - 7.7.2. Key Executives
  - 7.7.3. Company Snapshot
  - 7.7.4. Operating Business Segments
  - 7.7.5. Product Portfolio
  - 7.7.6. Business Performance
  - 7.7.7. Key Strategic Moves and Developments
- 7.8. Novartis AG
  - 7.8.1. Company Overview
  - 7.8.2. Key Executives
  - 7.8.3. Company Snapshot
  - 7.8.4. Operating Business Segments
  - 7.8.5. Product Portfolio
  - 7.8.6. Business Performance
  - 7.8.7. Key Strategic Moves and Developments
- 7.9. Bristol-Myers Squibb Company
  - 7.9.1. Company Overview
  - 7.9.2. Key Executives
  - 7.9.3. Company Snapshot
  - 7.9.4. Operating Business Segments
  - 7.9.5. Product Portfolio
  - 7.9.6. Business Performance
  - 7.9.7. Key Strategic Moves and Developments
- 7.10. Immunomedics, Inc.
  - 7.10.1. Company Overview
  - 7.10.2. Key Executives
  - 7.10.3. Company Snapshot
  - 7.10.4. Operating Business Segments
  - 7.10.5. Product Portfolio
  - 7.10.6. Business Performance
  - 7.10.7. Key Strategic Moves and Developments

LIST OF TABLES
TABLE 1. GLOBAL CELIAC DISEASE DRUGS MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 2. GLOBAL CELIAC DISEASE DRUGS MARKET FOR FIRST LINE OF TREATMENT, BY REGION, 2022-2032 ($MILLION)
TABLE 3. GLOBAL CELIAC DISEASE DRUGS MARKET FOR SECOND LINE OF TREATMENT, BY REGION, 2022-2032 ($MILLION)
TABLE 4. GLOBAL CELIAC DISEASE DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 5. NORTH AMERICA CELIAC DISEASE DRUGS, BY REGION, 2022-2032 ($MILLION)
TABLE 6. NORTH AMERICA CELIAC DISEASE DRUGS, BY DRUGS, 2022-2032 ($MILLION)
TABLE 7. U.S. CELIAC DISEASE DRUGS, BY DRUGS, 2022-2032 ($MILLION)
TABLE 8. CANADA CELIAC DISEASE DRUGS, BY DRUGS, 2022-2032 ($MILLION)
TABLE 9. MEXICO CELIAC DISEASE DRUGS, BY DRUGS, 2022-2032 ($MILLION)
TABLE 10. EUROPE CELIAC DISEASE DRUGS, BY REGION, 2022-2032 ($MILLION)
TABLE 11. EUROPE CELIAC DISEASE DRUGS, BY DRUGS, 2022-2032 ($MILLION)
TABLE 12. FRANCE CELIAC DISEASE DRUGS, BY DRUGS, 2022-2032 ($MILLION)
TABLE 13. GERMANY CELIAC DISEASE DRUGS, BY DRUGS, 2022-2032 ($MILLION)
TABLE 14. ITALY CELIAC DISEASE DRUGS, BY DRUGS, 2022-2032 ($MILLION)
TABLE 15. SPAIN CELIAC DISEASE DRUGS, BY DRUGS, 2022-2032 ($MILLION)
TABLE 16. UK CELIAC DISEASE DRUGS, BY DRUGS, 2022-2032 ($MILLION)
TABLE 17. RUSSIA CELIAC DISEASE DRUGS, BY DRUGS, 2022-2032 ($MILLION)
TABLE 18. REST OF EUROPE CELIAC DISEASE DRUGS, BY DRUGS, 2022-2032 ($MILLION)
TABLE 19. ASIA-PACIFIC CELIAC DISEASE DRUGS, BY REGION, 2022-2032 ($MILLION)
TABLE 20. ASIA-PACIFIC CELIAC DISEASE DRUGS, BY DRUGS, 2022-2032 ($MILLION)
TABLE 21. CHINA CELIAC DISEASE DRUGS, BY DRUGS, 2022-2032 ($MILLION)
TABLE 22. JAPAN CELIAC DISEASE DRUGS, BY DRUGS, 2022-2032 ($MILLION)
TABLE 23. INDIA CELIAC DISEASE DRUGS, BY DRUGS, 2022-2032 ($MILLION)
TABLE 24. SOUTH KOREA CELIAC DISEASE DRUGS, BY DRUGS, 2022-2032 ($MILLION)
TABLE 25. AUSTRALIA CELIAC DISEASE DRUGS, BY DRUGS, 2022-2032 ($MILLION)
TABLE 26. THAILAND CELIAC DISEASE DRUGS, BY DRUGS, 2022-2032 ($MILLION)
TABLE 27. MALAYSIA CELIAC DISEASE DRUGS, BY DRUGS, 2022-2032 ($MILLION)
TABLE 28. INDONESIA CELIAC DISEASE DRUGS, BY DRUGS, 2022-2032 ($MILLION)
TABLE 29. REST OF ASIA PACIFIC CELIAC DISEASE DRUGS, BY DRUGS, 2022-2032 ($MILLION)
TABLE 30. LAMEA CELIAC DISEASE DRUGS, BY REGION, 2022-2032 ($MILLION)
TABLE 31. LAMEA CELIAC DISEASE DRUGS, BY DRUGS, 2022-2032 ($MILLION)
TABLE 32. BRAZIL CELIAC DISEASE DRUGS, BY DRUGS, 2022-2032 ($MILLION)
TABLE 33. SOUTH AFRICA CELIAC DISEASE DRUGS, BY DRUGS, 2022-2032 ($MILLION)
TABLE 34. SAUDI ARABIA CELIAC DISEASE DRUGS, BY DRUGS, 2022-2032 ($MILLION)
TABLE 35. UAE CELIAC DISEASE DRUGS, BY DRUGS, 2022-2032 ($MILLION)
TABLE 36. ARGENTINA CELIAC DISEASE DRUGS, BY DRUGS, 2022-2032 ($MILLION)
TABLE 37. REST OF LAMEA CELIAC DISEASE DRUGS, BY DRUGS, 2022-2032 ($MILLION)
TABLE 38. F. HOFFMANN-LA ROCHE: KEY EXECUTIVES
TABLE 39. F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT
TABLE 40. F. HOFFMANN-LA ROCHE: OPERATING SEGMENTS
TABLE 41. F. HOFFMANN-LA ROCHE: PRODUCT PORTFOLIO
TABLE 42. F. HOFFMANN-LA ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 43. MERCK AND CO., INC.: KEY EXECUTIVES
TABLE 44. MERCK AND CO., INC.: COMPANY SNAPSHOT
TABLE 45. MERCK AND CO., INC.: OPERATING SEGMENTS
TABLE 46. MERCK AND CO., INC.: PRODUCT PORTFOLIO
TABLE 47. MERCK AND CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 48. JOHNSON AND JOHNSON: KEY EXECUTIVES
TABLE 49. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
TABLE 50. JOHNSON AND JOHNSON: OPERATING SEGMENTS
TABLE 51. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
TABLE 52. JOHNSON AND JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 53. BIOLINERX LTD.: KEY EXECUTIVES
TABLE 54. BIOLINERX LTD.: COMPANY SNAPSHOT
TABLE 55. BIOLINERX LTD.: OPERATING SEGMENTS
TABLE 56. BIOLINERX LTD.: PRODUCT PORTFOLIO
TABLE 57. BIOLINERX LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 58. PFIZER INC.: KEY EXECUTIVES
TABLE 59. PFIZER INC.: COMPANY SNAPSHOT
TABLE 60. PFIZER INC.: OPERATING SEGMENTS
TABLE 61. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 62. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 63. INNOVATE BIOPHARMACEUTICALS: KEY EXECUTIVES
TABLE 64. INNOVATE BIOPHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 65. INNOVATE BIOPHARMACEUTICALS: OPERATING SEGMENTS
TABLE 66. INNOVATE BIOPHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 67. INNOVATE BIOPHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 68. IMMUSANT, INC.: KEY EXECUTIVES
TABLE 69. IMMUSANT, INC.: COMPANY SNAPSHOT
TABLE 70. IMMUSANT, INC.: OPERATING SEGMENTS
TABLE 71. IMMUSANT, INC.: PRODUCT PORTFOLIO
TABLE 72. IMMUSANT, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 73. NOVARTIS AG: KEY EXECUTIVES
TABLE 74. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 75. NOVARTIS AG: OPERATING SEGMENTS
TABLE 76. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 77. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 78. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
TABLE 79. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
TABLE 80. BRISTOL-MYERS SQUIBB COMPANY: OPERATING SEGMENTS
TABLE 81. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
TABLE 82. BRISTOL-MYERS SQUIBB COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 83. IMMUNOMEDICS, INC.: KEY EXECUTIVES
TABLE 84. IMMUNOMEDICS, INC.: COMPANY SNAPSHOT
TABLE 85. IMMUNOMEDICS, INC.: OPERATING SEGMENTS
TABLE 86. IMMUNOMEDICS, INC.: PRODUCT PORTFOLIO
TABLE 87. IMMUNOMEDICS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES
FIGURE 1. GLOBAL CELIAC DISEASE DRUGS MARKET SEGMENTATION
FIGURE 2. GLOBAL CELIAC DISEASE DRUGS MARKET
FIGURE 3. SEGMENTATION CELIAC DISEASE DRUGS MARKET
FIGURE 4. TOP INVESTMENT POCKET IN CELIAC DISEASE DRUGS MARKET
FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
FIGURE 8. LOW THREAT OF SUBSTITUTION
FIGURE 9. HIGH COMPETITIVE RIVALRY
FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALCELIAC DISEASE DRUGS MARKET
FIGURE 11. CELIAC DISEASE DRUGS MARKET SEGMENTATION, BY BY DRUGS
FIGURE 12. CELIAC DISEASE DRUGS MARKET FOR FIRST LINE OF TREATMENT, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 13. CELIAC DISEASE DRUGS MARKET FOR SECOND LINE OF TREATMENT, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 14. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
FIGURE 15. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
FIGURE 16. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
FIGURE 17. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 18. COMPETITIVE DASHBOARD
FIGURE 19. COMPETITIVE HEATMAP: CELIAC DISEASE DRUGS MARKET
FIGURE 20. Top player positioning, 2022
FIGURE 21. F. HOFFMANN-LA ROCHE: NET SALES, 2020-2022 ($MILLION)
FIGURE 22. F. HOFFMANN-LA ROCHE: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 23. F. HOFFMANN-LA ROCHE: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 24. MERCK AND CO., INC.: NET SALES, 2020-2022 ($MILLION)
FIGURE 25. MERCK AND CO., INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 26. MERCK AND CO., INC.: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 27. JOHNSON AND JOHNSON: NET SALES, 2020-2022 ($MILLION)
FIGURE 28. JOHNSON AND JOHNSON: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 29. JOHNSON AND JOHNSON: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 30. BIOLINERX LTD.: NET SALES, 2020-2022 ($MILLION)
FIGURE 31. BIOLINERX LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 32. BIOLINERX LTD.: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 33. PFIZER INC.: NET SALES, 2020-2022 ($MILLION)
FIGURE 34. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 35. PFIZER INC.: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 36. INNOVATE BIOPHARMACEUTICALS: NET SALES, 2020-2022 ($MILLION)
FIGURE 37. INNOVATE BIOPHARMACEUTICALS: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 38. INNOVATE BIOPHARMACEUTICALS: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 39. IMMUSANT, INC.: NET SALES, 2020-2022 ($MILLION)
FIGURE 40. IMMUSANT, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 41. IMMUSANT, INC.: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 42. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
FIGURE 43. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 44. NOVARTIS AG: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 45. BRISTOL-MYERS SQUIBB COMPANY: NET SALES, 2020-2022 ($MILLION)
FIGURE 46. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 47. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 48. IMMUNOMEDICS, INC.: NET SALES, 2020-2022 ($MILLION)
FIGURE 49. IMMUNOMEDICS, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 50. IMMUNOMEDICS, INC.: REVENUE SHARE, BY REGION, 2032 (%)

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
Technologically sophisticated and reliable insights through well audited and veracious research methodology
Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

Patent and regulatory databases for understanding of technical & legal developments
Scientific and technical writings for product information and related preemptions
Regional government and statistical databases for macro analysis
Authentic new articles, web-casts and other related releases for market evaluation
Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

Validates and improves the data quality and strengthens research proceeds
Further develops analyst team’s market understanding and expertise
Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

Chief executives and VPs of leading corporations specific to industry
Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

U.S.-Canada Toll-free: +1-800-792-5285
Int'l :	+1-503-894-6022
Europe :	+44-845-528-1300
Email :	help@alliedmarketresearch.com

Life Sciences	Construction & Manufacturing	Semiconductor & Electronics
Consumer Goods	Food & Beverages	Automotive & Tarnsportation
Materials & Chemicals	Energy & Power	ICT & Media
Aerospace & Defense	BFSI
You must check at least one industry.

Your Shopping Cart Is Empty

Continue Shopping

Celiac Disease Drugs Market Global Opportunity Analysis and Industry Forecast, 2023-2032

2023

Celiac Disease Drugs Market

Celiac Disease Drugs Market

by Drugs (First Line of Treatment, Second Line of Treatment): Global Opportunity Analysis and Industry Forecast, 2023-2032

COVID-19

CHAPTER 1: INTRODUCTION

1.1. Report Description

1.2. Key Market Segments

1.3. Key Benefits

1.4. Research Methodology

1.4.1. Primary Research

1.4.2. Secondary Research

1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

3.1. Market Definition and Scope

3.2. Key Findings

3.2.1. Top Investment Pockets

3.2.2. Top Winning Strategies

3.3. Porter's Five Forces Analysis

3.3.1. Bargaining Power of Suppliers

3.3.2. Threat of New Entrants

3.3.3. Threat of Substitutes

3.3.4. Competitive Rivalry

3.3.5. Bargaining Power among Buyers

3.5. Market Dynamics

3.5.1. Drivers

3.5.2. Restraints

3.5.3. Opportunities

3.6. COVID-19 Impact Analysis

CHAPTER 4: CELIAC DISEASE DRUGS MARKET, BY DRUGS

4.1. Market Overview

4.1.1 Market Size and Forecast, By Drugs

4.2. First Line Of Treatment

4.2.1. Key Market Trends, Growth Factors and Opportunities

4.2.2. Market Size and Forecast, By Region

4.2.3. Market Share Analysis, By Country

4.3. Second Line Of Treatment

4.3.1. Key Market Trends, Growth Factors and Opportunities

4.3.2. Market Size and Forecast, By Region

4.3.3. Market Share Analysis, By Country

CHAPTER 5: CELIAC DISEASE DRUGS MARKET, BY REGION

5.1. Market Overview

5.1.1 Market Size and Forecast, By Region

5.2. North America

5.2.1. Key Market Trends and Opportunities

5.2.2. Market Size and Forecast, By Drugs

5.2.3. Market Size and Forecast, By Country

5.2.4. U.S. Celiac Disease Drugs Market

5.2.4.1. Market Size and Forecast, By Drugs

5.2.5. Canada Celiac Disease Drugs Market

5.2.5.1. Market Size and Forecast, By Drugs

5.2.6. Mexico Celiac Disease Drugs Market

5.2.6.1. Market Size and Forecast, By Drugs

5.3. Europe

5.3.1. Key Market Trends and Opportunities

5.3.2. Market Size and Forecast, By Drugs

5.3.3. Market Size and Forecast, By Country

5.3.4. France Celiac Disease Drugs Market

5.3.4.1. Market Size and Forecast, By Drugs

5.3.5. Germany Celiac Disease Drugs Market

5.3.5.1. Market Size and Forecast, By Drugs

5.3.6. Italy Celiac Disease Drugs Market

5.3.6.1. Market Size and Forecast, By Drugs

5.3.7. Spain Celiac Disease Drugs Market

5.3.7.1. Market Size and Forecast, By Drugs

5.3.8. UK Celiac Disease Drugs Market

5.3.8.1. Market Size and Forecast, By Drugs

5.3.9. Russia Celiac Disease Drugs Market

5.3.9.1. Market Size and Forecast, By Drugs

5.3.10. Rest Of Europe Celiac Disease Drugs Market

5.3.10.1. Market Size and Forecast, By Drugs

5.4. Asia-Pacific

5.4.1. Key Market Trends and Opportunities

5.4.2. Market Size and Forecast, By Drugs

5.4.3. Market Size and Forecast, By Country

Celiac Disease Drugs Market
Global Opportunity Analysis and Industry Forecast, 2023-2032